A246960 Stock Overview
Engages in the development and sale of medical sealant products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
SCL Science Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩8,440.00 |
| 52 Week High | ₩11,850.00 |
| 52 Week Low | ₩7,600.00 |
| Beta | 0.78 |
| 11 Month Change | -2.99% |
| 3 Month Change | -8.26% |
| 1 Year Change | -6.43% |
| 33 Year Change | -27.86% |
| 5 Year Change | -36.54% |
| Change since IPO | -56.38% |
Recent News & Updates
Shareholder Returns
| A246960 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | 4.2% | 8.1% | 2.9% |
| 1Y | -6.4% | 11.5% | -2.8% |
Return vs Industry: A246960 underperformed the KR Medical Equipment industry which returned 11.5% over the past year.
Return vs Market: A246960 underperformed the KR Market which returned -2.8% over the past year.
Price Volatility
| A246960 volatility | |
|---|---|
| A246960 Average Weekly Movement | 3.3% |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A246960 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A246960's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 44 | Moon Lee | www.innotherapy.com |
SCL Science Inc., engages in the development and sale of medical sealant products in South Korea. The company’s products include InnoSEAL, an externally applied hemostatic agent; InnoSEAL Plus, an absorbable hemostatic pad; EndoSil, an absorbable hemostatic agent used for the gastrointestinal oozing bleeding; GellySil, a biomaterial and the proprietary material product. It also provides Film-type surgical sealant to complete sealing of anastomosis site; STOP needle, a self-sealing needle for general and ophthalmic use; wound dressing used for chronic wounds, burns, etc.; and Gene therapy, a bio-therapeutics delivery system.
SCL Science Inc. Fundamentals Summary
| A246960 fundamental statistics | |
|---|---|
| Market cap | ₩61.47b |
| Earnings (TTM) | -₩3.13b |
| Revenue (TTM) | ₩3.77b |
16.3x
P/S Ratio-19.6x
P/E RatioIs A246960 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A246960 income statement (TTM) | |
|---|---|
| Revenue | ₩3.77b |
| Cost of Revenue | ₩2.64b |
| Gross Profit | ₩1.14b |
| Other Expenses | ₩4.27b |
| Earnings | -₩3.13b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -429.79 |
| Gross Margin | 30.15% |
| Net Profit Margin | -82.96% |
| Debt/Equity Ratio | 23.8% |
How did A246960 perform over the long term?
See historical performance and comparison